Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Public ClinicalTrials.gov record NCT05334368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
Study identification
- NCT ID
- NCT05334368
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Interventions
- Depemokimab Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2022
- Primary completion
- Dec 18, 2028
- Completion
- Dec 18, 2028
- Last update posted
- Nov 24, 2025
2022 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | San Diego | California | 920237 | Recruiting |
| GSK Investigational Site | Atlanta | Georgia | 30322 | Recruiting |
| GSK Investigational Site | Boston | Massachusetts | 02111 | Recruiting |
| GSK Investigational Site | Southfield | Michigan | 48075 | Withdrawn |
| GSK Investigational Site | Rochester | Minnesota | 55905 | Withdrawn |
| GSK Investigational Site | Manhasset | New York | 11030 | Completed |
| GSK Investigational Site | Cincinnati | Ohio | 45229 | Recruiting |
| GSK Investigational Site | Columbus | Ohio | 43212 | Recruiting |
| GSK Investigational Site | Charleston | South Carolina | 29425 | Recruiting |
| GSK Investigational Site | Nashville | Tennessee | 37208 | Completed |
| GSK Investigational Site | Salt Lake City | Utah | 84132 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05334368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05334368 live on ClinicalTrials.gov.